Will the new COVID-19 antiviral be accessible?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Will the new COVID-19 antiviral be accessible?
-
ナレーター：
-
著者：
In June, the Food and Drug Administration approved the drug Xocova (ensitrelvir) as the very first post-exposure prophylaxis for Sars-CoV-2, and if taken within 72 hours, it could stop a SARS-CoV-2 infection in its tracks. The drug is also being studied as a potential Long COVID treatment and even maybe as a preventative. But how accessible will this drug be?
In this episode of Still Here, Betsy Ladyzhets talks to co-host and Sick Times co-founder Miles Griffis about his reporting on the drug, the manufacturers, the studies behind it, and what it could mean for the disease.
Subscribe to Still Here wherever you get your podcasts, and leave us a review letting us know what you think of the show.
Links Mentioned:
- FDA approves COVID-19 antiviral Xocova as PEP. But will it be accessible? - The Sick Times
Research updates, June 23 - The Sick Times